Cytokinetics, Incorporated (CYTK)

66,06 +1,72 (+2,67%) A partir del 10:15AM EDT. Mercado abierto.

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000
https://www.cytokinetics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 423

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Robert I. Blum	CEO, President, Principal Financial Officer & Director	1,33M	9,61M	1964
Mr. Robert C. Wong	VP & Chief Accounting Officer	495,72k	N/A	1968
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development	839,66k	586,17k	1964
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer	752,84k	N/A	1969
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board	21,94k	N/A	1942
Mr. Jeff Lotz	Vice President of Sales & Operations	N/A	N/A	N/A
Mr. Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	N/A	N/A	N/A
Mr. Steven M. Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	N/A	N/A	1959
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer	N/A	N/A	N/A
Mr. John O. Faurescu Esq.	VP, Associate General Counsel & Corporate Secretary	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Cytokinetics, Incorporated, a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 2; Tablero: 3; Derechos de los accionistas: 7; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.